A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8&lt;sup&gt;+&lt;/sup&gt; infiltration in glioma. This evidence concerns the gene CD8A and central nervous system cancer.